Interv Akut Kardiol. 2017;16(3):106-108 | DOI: 10.36290/kar.2017.019

Bioresorbable vascular scaffold – good idea worth further effort

Viktor Kočka
III. interní kardiologická klinika, 3. LF UK a FN Královské Vinohrady, Praha

Currently, absorbable stents should not be used in routine clinical practice since their safety has been questioned. This fact, however,should not stand in the way of further development of this intuitively correct concept since long-term data after implantation ofpermanent metal stents show a constantly increasing incidence of clinical events. In the future, a better technique of implantationof absorbable stents can be expected and technological progress is also very promising. The author summarizes several potentialadvantages of the absence of a permanent foreign body in a coronary artery. The routine use of absorbable stents can be consideredin the future if we manage to demonstrate the safety and efficacy of this technology at the point of complete resorption.

Keywords: percutaneous coronary intervention, bioresorbable stent

Accepted: October 16, 2017; Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kočka V. Bioresorbable vascular scaffold – good idea worth further effort. Interv Akut Kardiol. 2017;16(3):106-108. doi: 10.36290/kar.2017.019.
Download citation

References

  1. Testa L, Latib A, Montone RA, Colombo A, Bedogni F. Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease. Circ Cardiovasc Interv. 2016; 9(7). Go to original source... Go to PubMed...
  2. Kocka V, Tousek P, Widimsky P. Absorb bioresorbable stents for the treatment of coronary artery disease. Expert Rev Med Devices. 2015; 12(5): 545-557. Go to original source... Go to PubMed...
  3. Tenekecioglu E, Farooq V, Bourantas CV, Silva RC, Onuma Y, Yilmaz M, et al. Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovasc Disord. 2016; 16: 38. Go to original source... Go to PubMed...
  4. Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable Vascular Scaffolds for Coronary Revascularization. Circulation. 2016; 134(2): 168-182. Go to original source... Go to PubMed...
  5. Sotomi Y, Onuma Y, Collet C, Tenekecioglu E, Virmani R, Kleiman NS, et al. Bioresorbable Scaffold: The Emerging Reality and Future Directions. Circ Res. 2017; 120(8): 1341-1352. Go to original source... Go to PubMed...
  6. Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016; 388(10059): 2479-2491. Go to original source... Go to PubMed...
  7. Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, AJ IJ, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med. 2017; 376(24): 2319-2328. Go to original source... Go to PubMed...
  8. Yamaji K, Raber L, Zanchin T, Spitzer E, Zanchin C, Pilgrim T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016; 37(45): 3386-3395. Go to original source... Go to PubMed...
  9. Brodie BR, Pokharel Y, Garg A, Kissling G, Hansen C, Milks S, et al. Very late hazard with stenting versus balloon angioplasty for ST-elevation myocardial infarction: a 16-year single-center experience. J Interv Cardiol. 2014; 27(1): 21-28. Go to original source... Go to PubMed...
  10. Everaert B, Wykrzykowska JJ, Koolen J, van der Harst P, den Heijer P, Henriques JP, et al. Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions : 2017 revision. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2017; 25(7-8): 419-428. Go to original source... Go to PubMed...
  11. Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol. 2016; 67(8): 921-931. Go to original source... Go to PubMed...
  12. Abizaid A, Costa RA, Schofer J, Ormiston J, Maeng M, Witzenbichler B, et al. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions. JACC Cardiovasc Interv. 2016; 9(6): 565-574. Go to original source... Go to PubMed...
  13. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014; 7(1): 89-99. Go to original source... Go to PubMed...
  14. Haude M, Erbel R, Erne P, Verheye S, Degen H, Vermeersch P, et al. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. EuroIntervention. 2016; 12(2): e160-166. Go to original source... Go to PubMed...
  15. Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. Eur Heart J. 2016; 37(35): 2701-2709. Go to original source... Go to PubMed...
  16. Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet. 2016; 387(10013): 31-39. Go to original source...
  17. Waksman R, Prati F, Bruining N, Haude M, Bose D, Kitabata H, et al. Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment. Circ Cardiovasc Interv. 2013; 6(6): 644-653. Go to original source... Go to PubMed...
  18. Haude M, Erbel R, Erne P, Verheye S, Degen H, Bose D, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013; 381(9869): 836-844. Go to original source...
  19. Fajadet J, Haude M, Joner M, Koolen J, Lee M, Tolg R, et al. Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016. EuroIntervention. 2016; 12(7): 828-833. Go to original source... Go to PubMed...
  20. Waksman R, Lipinski MJ, Acampado E, Cheng Q, Adams L, Torii S, et al. Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model. Circ Cardiovasc Interv. 2017; 10(8). Go to original source...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.